References Uhs
1. Brownlee, G.G. and Giangrande, P.L.F, Clotting factors VIII and IX, in Recombinant Drug Proteins Milestones in Drug Therapy , Buckel, P., Ed., Birkh user Verlag, Basel, Switzerland, 2. Thompson, A.R., Structure, function, and molecular defects of Factor IX, Blood, 67, 565-572, 1986. 3. Bowen, D.J., Haemophilia A and haemophilia B Molecular insights, J. Clin. Pathol Mol. Pathol., 55, 1-18, 2002. 4. Furie, B. and Furie, B.C., The molecular basis of blood coagulation, Cell, 53, 505-518, 1988....
HighPurity pdFIX Products
Improvements in methods to separate FIX from crude preparations led to the development of high-purity pdFIX concentrates, which increased the safety profiles of treatments available for hemophilia B. High-purity pdFIX concentrates became available for treatment of hemophilia B in the mid-1970s, and have proven very effective in treating bleeding episodes 1,6 . The use of enzyme replacement therapy ERT , through administration of PCCs and pdFIX products, to treat hemophilia has no doubt enhanced...
References Ujd
1. Morrissey, J.H., et al., Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation, Blood, 81, 734-744, 1993. 2. Wildgoose, P., et al., Measurement of basal levels of factor VIIa in hemophilia A and B patients, Blood, 80, 25-28, 1992. 3. Davie, E.W., Fujikawa, K., and Kisiel, W., The coagulation cascade Initiation, maintenance, and regulation, Biochemistry, 30, 10363-10370, 1991. 4. Eigenbrot, C. and...
Adverse Effects Interactions and Pharmacokinetics
Dosages of up to 30 mg rhDNase I per day were well tolerated in healthy volunteers and CF patients 69,87 . Severe bronchospasms or anaphylactic reactions, as seen after inhalation of bovine DNase I, have never been observed with rhDNase I. The most common adverse effects reported after daily inhalation of 2.5 mg rhDNase I were voice alterations hoarseness , pharyngitis, rash, laryngitis, and conjunctivitis 74,76,78 . All these events are generally mild and transient. In patients with severe...
Purification
The purification method for rFVII from the cell culture medium has to ensure the removal of non-rFVII proteins and the specific activation of rFVII to rFVIIa as noted above. The following purification procedure Figure 10.6 was developed to meet these criteria 1 Culture medium is pH-adjusted and loaded onto a Q-Sepharose FF column. This step mainly functions to concentrate the protein. 2 Virus inactivation is ensured by treatment with a detergent. 3 rFVII is then loaded on an immunoaffinity...
Info Gff
26. Berg, D.T., McClure, D.B., and Grinnell, B.W., High-level expression of secreted proteins from cell adapted to serum-free suspension culture, Biotech., 6, 972-978, 1993. 27. Walls, J.D. and Grinnell, B.W., A rapid and versatile method for the detection and isolation of mammalian cell lines secreting recombinant proteins, Biotechniques, 8, 138-142, 1990. 28. Walls, J.D., et al., Amplification of multicistronic plasmids in the human 293 cell line and secretion of correctly processed...
References Uid
1. Kreuder, V., et al., Isolation, characterization and crystallization of deoxyribonuclease-I from bovine and rat parotid-gland and its interaction with rabbit skeletal-muscle actin, Eur. J. Biochem., 139, 389-400, 1984. 2. Shiokawa, D. and Tanuma, S., Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis, Biochemistry, 40, 143-152, 2001. 3. Evans, C.J. and Aguilera, R.J., DNase II Genes, enzymes and function, Gene, 322, 1-15, 2003. 4. Nadano,...
DNase I in NonCF Respiratory Diseases
Highly viscoelastic lung mucus causes many other respiratory disorders like atelectasis, bronchiectasis, bronchiolitis, bronchitis, and primary ciliary dyskinesia PCD , giving rise to suffering and even morbidity. Under these conditions, the high viscidity of the lung secretions is often also due to high DNA concentrations, a result of a neutrophil-dominated airway inflammation. Consequently, rhDNase I may be of benefit to these patients. However, unlike the situation in CF, only a few...
Table 14
Some Enzymes Used Directly or Indirectly as Diagnostic Reagents Their Sources and Likely Applications Acetyl cholinesterase Alcohol dehydrogenase Alkaline phosphatase Arginase Calf intestine and kidney, Recombinant Picca sp. Beef liver Recombinant Streptomyces sp. Rabbit muscle, beef heart, pig heart Analysis of organophosphorous compounds such as pesticides Determination of alcohol levels in biological fluids Conjugation to antibodies allows its use as an indicator in ELISA systems...
APC Mechanism and Sepsis
As discussed above, homeostasis is lost in sepsis, resulting in an uncontrolled cascade of coagulation, inflammation, and endothelial cell dysfunction. APC functions by reducing thrombin generation and, via cell signaling, may modulate anti-inflammatory and cyto-protective mechanisms. Considering the prominent role of microvascular coagulation in sepsis and the major role of protein C in normal hemostasis, a major mechanism for the benefit of rhAPC is likely to be its direct antithrombotic...
Info Eji
disadvantages, glucoamylase CLECs were developed which displayed enhanced thermostability and significantly increased activity at higher temperatures 157 . This technique has been applied to various enzymes including lipases, subtilisin, and thermolysin reviewed in 158 . Attachment of the protein to multiple sites of a suitable polymer is another chemical modification approach to enhance enzyme thermostability. Gomez et al. 159 used such an approach to improve the thermostability of a yeast...
Figure 106
Flow diagram of the manufacturing process of recombinant factor VIIa. membrane-bound FXa 31 . In the rFVIIa production process, rFVII single chain is converted into rFVIIa two chain during the purification process by autocleavage. Sequence analysis has shown that the two-chain form is identical to pdFVIIa. The purification process is optimized so that rFVII is converted into rFVIIa with almost 100 yield 21,32 . The degree of activation seems to depend on the amount of rFVII loaded per volume of...
Production and Stability of rhDNase I
The first step in the production of rhDNase I is the construction of a eukaryotic expression vector comprising the rhDNase I gene and a selection gene, dihydrofolate reductase DHFR . Subsequently, CHO cells lacking the DHFR gene are transfected with this vector and put into a selection medium lacking essential nucleotides. This leads to the selection of transformed cells 165 . These transformed cells are further grown in an optimized medium and in conditions that guarantee a maximal expression...
Table 15
Industrial Sectors in Which Protease Enzymes are Applied Laundry detergent additive Leather manufacture Cheese manufacture Meat processing Beverage industry Baking Promotes catalytic degradation of protein-based clothing stains To dehair animal hides and to soften bate leather 1.4.2 The Application of Proteases in the Food and Drink Industry Rennin also known as chymosin is an important commercial protease that is used in the manufacture of cheese. This enzyme catalyzes limited cleavage of...
Rasburicase Expression And Purification
8.2 Biochemical Characteristics of the 8.2.1 Structure 8.2.2 Kinetic 8.2.3 Related 8.3 Indications for which the Enzyme is 8.3.1.1 Mechanism of Uric Acid 8.3.1.2 Consequences of 8.3.2 Medical Conditions Requiring Uricolytic 8.3.2.2 Diseases and Causes of Acute 8.4 Developmental History of the Enzyme 8.4.1.1 Mechanism of 8.4.2 Safety of 8.4.3 Results of Rasburicase 8.5 Characteristics of the Enzyme's Producer Cell 8.5.1 The Expression Vector 8.5.1.1 The Urate Oxidase-Encoding 8.5.2 The Host...
Development of Ceredase
With the proof of concept demonstrated, significant effort was required to scale up the extraction and purification of placental glucocerebrosidase to make it clinically and commercially viable. The magnitude of this challenge can be appreciated by the fact that it took 20,000 placentas to extract enough p-glucocerebrosidase to treat 1 patient for 1 year. Genzyme Corporation adapted the purification and carbohydrate remodeling schemes developed by Brady, et al., to improve both the purification...
DNase I in Wound Healing and Cancer
An ointment Elase or Fibrolan containing bovine DNase I and bovine fibrinolysin has been used clinically as a debriding agent in a variety of inflammatory and infected lesions 155 . The combination of these two enzymes was based on the observation that purulent exudates of infected lesions consist largely of fibrinous material and DNA. The ointment improved the healing of infected accidental or surgical wounds 156 , ulcerative lesions 157,158 , and second- and third-degree burns 159 . However,...
Table 31
FIGURE 3.1 The fibrinolytic process. TABLE 3.2 FIGURE 3.1 The fibrinolytic process. TABLE 3.2 Finger domain Promotes high-affinity binding to fibrin Protease domain Plasminogen specific proteolytic activity Epidermal growth factor domain Binds hepatic receptors, hence accelerating hepatic clearance Kringle-1 domain Associated with receptor binding Kringle-2 domain Allows stimulation by fibrin of proteolytic activity receptors, thereby accelerating hepatic clearance from the plasma. The...
Tenecteplase
Tenecteplase is an engineered, second-generation tPA-derived thrombolytic produced in a CHO cell line 39 . The 527-amino acid glycoprotein differs from native tPA by 1 substitution of Thr103 with Asn, 2 substitution of Asn117 with Glu, and 3 replacement of residues 296 to 299 with four Ala residues. The first two modifications reside in the K1 domain whereas residues 296 to 299 reside in the protease domain. The changes have been introduced by site-directed mutagenesis of a cDNA coding for...
Info Jbc
8. Rajput, B., et al., Chromosomal locations of human tissue plasminogen activator and urokinase genes, Science, 230, 672-674, 1985. 9. Smalling, R.W., Molecular biology of plasminogen activators What are the clinical implications of drug design , Am. J. Cardiol., 78 Suppl. 12A , 2-7, 1996. 10. Waller, M. and Kohnert, U., Reteplase, a recombinant plasminogen activator, in Biopharmaceuticals, An Industrial Perspective, Walsh, G. and Murphy, B., Eds., Kluwer Academic Publishers, Dordrecht, The...